{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:34Z","timestamp":1792004374299,"version":"4.4.0"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201500029C"],"award-info":[{"award-number":["HHSO100201500029C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,8,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Aztreonam-avibactam, a fixed-ratio (3:1) \u03b2-lactam\/\u03b2-lactamase inhibitor combination, was approved in Europe in 2024 for adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection, hospital-acquired\/ventilator-associated pneumonia, and other infections due to aerobic gram-negative organisms with limited treatment options. Pharmacokinetic data from two phase 3 trials were added to previous data to develop a simultaneous aztreonam and avibactam population pharmacokinetic model. The final model was used to simulate exposures by infection type and renal function and estimate the joint probability of pharmacodynamic target attainment (PTA) for phase 3 patients (aztreonam 60%\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      T &gt;MIC\n                      <jats:sub>ATM-AVI<\/jats:sub>\n                      of 8 mg\/L and avibactam 50%\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      T &gt;C\n                      <jats:sub>T<\/jats:sub>\n                      of 2.5 mg\/L). Additional simulations evaluated simplified loading doses, regimens for end-stage renal disease, and ceftazidime-avibactam + aztreonam regimens. The final model included 4,914 aztreonam plasma samples (431 subjects) and 18,222 avibactam plasma samples (2,635 subjects). A two-compartment model with zero-order infusion and first-order elimination best fit the data. Time-varying creatinine clearance was a key covariate on clearance for both drugs, whereas infection type was a key covariate on clearance and volume, with the lowest exposures observed in patients with cIAI. Final aztreonam-avibactam dose regimens achieved joint PTA 89% to &gt;99% at steady state across renal function groups. Ceftazidime-avibactam + aztreonam dose regimens proposed by the Infectious Diseases Society of America (IDSA) achieved joint PTA &lt;85% due to insufficient avibactam exposures. Approved aztreonam-avibactam dose regimens (single loading dose and regular maintenance doses, all 3 h intravenous infusions) are optimized for joint PTA across renal function groups and infection types.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>CLINICAL TRIALS<\/jats:title>\n                      <jats:p>\n                        This study is registered with ClinicalTrials.gov as\n                        <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT03329092\" document-id-type=\"clinical-trial-number\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03329092?cond=%20NCT03329092&amp;rank=1\">NCT03329092<\/jats:related-object>\n                        and\n                        <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT03580044\" document-id-type=\"clinical-trial-number\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03580044?cond=NCT03580044&amp;rank=1\">NCT03580044<\/jats:related-object>\n                        .\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01950-24","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T10:11:20Z","timestamp":1750241480000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["Population pharmacokinetic\/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients"],"prefix":"10.1128","volume":"69","author":[{"given":"Rujia","family":"Xie","sequence":"first","affiliation":[{"name":"Pfizer Ltd","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halley","family":"Rogers","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-5877","authenticated-orcid":true,"given":"Joseph W.","family":"Chow","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0999-1351","authenticated-orcid":false,"given":"Elena","family":"Soto","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Sandwich, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2554-9719","authenticated-orcid":true,"given":"Susan R.","family":"Raber","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["La Jolla, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"e_1_3_4_3_2","unstructured":"Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States 2019. Available from: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf"},{"key":"e_1_3_4_4_2","unstructured":"Centers for Disease Control and Prevention. 2022. COVID-19: U.S. impact on antimicrobial resistance special report 2022. U.S. Department of Health and Human Services Atlanta GA. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/119025\/cdc_119025_DS1.pdf"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz497"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00499-7"},{"key":"e_1_3_4_7_2","volume-title":"Efficacy and safety of aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2 lactamase (MBL) producing multidrug resistant gram-negative bacteria: phase 3 ASSEMBLE trial, abstr E0846","author":"Daikos GL","year":"2024","unstructured":"Daikos GL, Cisneros JM, Carmeli Y, Wang M, Leong CL, Pontikis K, Anderzhanova A, Florescu S, Kozlov R, Noriega ER, Psichogiou M, Rattanaumpawan P, Streinu-Cercel A, Ramasubramanian V, Arhin FF, Rogers H, Wible M, Leaney J, Jacobson D, Pypstra R, Chow JW. 2024. Efficacy and safety of aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2 lactamase (MBL) producing multidrug resistant gram-negative bacteria: phase 3 ASSEMBLE trial, abstr E0846. 34th ed. European Society of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain.","edition":"34"},{"key":"e_1_3_4_8_2","unstructured":"Pfizer. 2024. Summary of product characteristics: emblaveo 1.5 g\/0.5 g powder for concentrate for solution for infusion. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emblaveo-epar-product-information_en.pdf"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066618762747"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00578-9"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad305"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02446-17"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03609-x"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv132"},{"key":"e_1_3_4_15_2","volume-title":"Development of a simultaneous population pharmacokinetic model for aztreonam-avibactam, abstr 990","author":"Xie R","year":"2020","unstructured":"Xie R, Chan PLS, McFadyen LM, Raber S. 2020. Development of a simultaneous population pharmacokinetic model for aztreonam-avibactam, abstr 990. 30th ed. European Congress of Clinical Microbiology and Infectious Diseases, Paris, France.","edition":"30"},{"key":"e_1_3_4_16_2","unstructured":"Pfizer. 2023. Pharmacokinetic study of aztreonam-avibactam in severe renal impairment. Available from: https:\/\/clinicaltrials.gov\/study\/NCT0448662"},{"key":"e_1_3_4_17_2","unstructured":"Pfizer. 2023. Study to assess the pharmacokinetics safety and tolerability of aztreonam-avibactam in healthy chinese participants. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04973826"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_3_4_21_2","unstructured":"Beal S Sheiner LB Boeckmann RA Bauer RJ. 2009. NONMEM users guides. on CON plc Gaithersburg MD. Available from: https:\/\/nonmem.iconplc.com\/nonmem750"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2460"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1011970125687"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12850"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198814030-00003"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199426020-00003"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01522-06"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.810"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02187-18"},{"key":"e_1_3_4_30_2","volume-title":"Ceftazidime-avibactam population pharmacokinetic (PK) and PK-pharmacodynamic (PK\/PD) modelling and simulation to support paediatric dosing, abstr O1163","author":"Lovern M","year":"2019","unstructured":"Lovern M, Franceze R, Watson K, Riccobene T, Carrothers TJ, McFadyen LM, Vourvahis M, Chan P, Raber SR, Bradley J. 2019. Ceftazidime-avibactam population pharmacokinetic (PK) and PK-pharmacodynamic (PK\/PD) modelling and simulation to support paediatric dosing, abstr O1163. 29th ed. European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, the Netherlands.","edition":"29"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01989-12"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04191-14"},{"key":"e_1_3_4_34_2","unstructured":"Pfizer Inc. 2025. Highlights of prescribing information: EMBLAVEO (Aztreonam and Avibactam) for injection for intravenous use. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217906Orig1s000lbl.pdf"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-022-04400-z"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00592-18"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.06.018"},{"key":"e_1_3_4_38_2","volume-title":"In vitro activities of aztreonam-avibactam and comparator agents against metallo-\u03b2-lactamase-producing enterobacterales collected during the ATLAS global surveillance program, 2016-2020, abstr 01014","author":"Wise M","year":"2022","unstructured":"Wise M, Estabrook M, Arhin FF, Sahm D. 2022. In vitro activities of aztreonam-avibactam and comparator agents against metallo-\u03b2-lactamase-producing enterobacterales collected during the ATLAS global surveillance program, 2016-2020, abstr 01014. 32nd ed. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Lisbon, Portugal.","edition":"32"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad032"},{"key":"e_1_3_4_40_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2024. Addendum (May 2024) to EUCAST Breakpoint Tables v. 14.0. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/Aztreonam-avibactam_addendum_22_May_2024.pdf"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad725"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01950-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01950-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:39:00Z","timestamp":1773178740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01950-24"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,6]]}},"alternative-id":["10.1128\/aac.01950-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01950-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"2024-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01950-24"}}